The U.S. Food and Drug Administration (FDA) approved the drug Zanubrutinib (Zanubrutinib), for For patients with chronic lymphocytic leukemia (CLL) or small lymphocytic lymphoma (SLL), it is a more effective treatment option with fewer side effects than common CLL treatments. Two years after patients in the trial started treatment, more than 78% of patients who received zanubrutinib were alive without their cancer growing, compared with 66% of patients who received ibrutinib. Zanubrutinib is particularly effective in cancer patients with genetic mutations that often portend a poor prognosis.
.jpeg)
